Pozen Initiates Enrollment In Phase 3 Studies For PA32540
Pozen has initiated the enrollment for the Phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325mg of enteric coated aspirin and 40mg of immediate release
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
The company believes that the test will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes William Moffitt, president and chief executive